269 related articles for article (PubMed ID: 34371959)
1. Whey Protein Supplementation Improves the Glycemic Response and May Reduce Non-Alcoholic Fatty Liver Disease Related Biomarkers in Women with Polycystic Ovary Syndrome (PCOS).
Zumbro EL; Rao M; Balcom-Luker S; Broughton KS; LeMieux MJ
Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371959
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome.
Javed Z; Papageorgiou M; Deshmukh H; Kilpatrick ES; Mann V; Corless L; Abouda G; Rigby AS; Atkin SL; Sathyapalan T
Nutrients; 2019 Jan; 11(1):. PubMed ID: 30658483
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
[TBL] [Abstract][Full Text] [Related]
5. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Wang D; Nan N; Bing H; He B
Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
[TBL] [Abstract][Full Text] [Related]
6. Association Between Insulin Resistance Indices and Liver Function Parameters Among Women With Polycystic Ovary Syndrome.
Saei Ghare Naz M; Mousavi M; Firouzi F; Momenan AA; Azizi F; Ramezani Tehrani F
Endocrinol Diabetes Metab; 2024 May; 7(3):e490. PubMed ID: 38769719
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Harsha Varma S; Tirupati S; Pradeep TVS; Sarathi V; Kumar D
Diabetes Metab Syndr; 2019; 13(2):1065-1069. PubMed ID: 31336445
[TBL] [Abstract][Full Text] [Related]
8. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
9. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome.
Targher G; Solagna E; Tosi F; Castello R; Spiazzi G; Zoppini G; Muggeo M; Day CP; Moghetti P
J Endocrinol Invest; 2009 Sep; 32(8):695-700. PubMed ID: 19542757
[TBL] [Abstract][Full Text] [Related]
10. Hepatic manifestations of women with polycystic ovary syndrome.
Chen MJ; Ho HN
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
[TBL] [Abstract][Full Text] [Related]
11. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
[TBL] [Abstract][Full Text] [Related]
12. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome.
Zueff LF; Martins WP; Vieira CS; Ferriani RA
Ultrasound Obstet Gynecol; 2012 Mar; 39(3):341-7. PubMed ID: 21898634
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
[TBL] [Abstract][Full Text] [Related]
14. The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome.
He H; Feng J; Zhang S; Wang Y; Li J; Gao J; Cong J; Gong Y; Wu X
Front Endocrinol (Lausanne); 2021; 12():773781. PubMed ID: 35069437
[TBL] [Abstract][Full Text] [Related]
15. Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome.
Belan M; Pelletier C; Baillargeon JP
Metab Syndr Relat Disord; 2017 Apr; 15(3):145-152. PubMed ID: 28339345
[TBL] [Abstract][Full Text] [Related]
16. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.
Robinson S; Henderson AD; Gelding SV; Kiddy D; Niththyananthan R; Bush A; Richmond W; Johnston DG; Franks S
Clin Endocrinol (Oxf); 1996 Mar; 44(3):277-84. PubMed ID: 8729522
[TBL] [Abstract][Full Text] [Related]
17. Effects of vitamin D supplementation in women with polycystic ovary syndrome: a review.
Menichini D; Facchinetti F
Gynecol Endocrinol; 2020 Jan; 36(1):1-5. PubMed ID: 31187648
[TBL] [Abstract][Full Text] [Related]
18. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.
Asemi Z; Foroozanfard F; Hashemi T; Bahmani F; Jamilian M; Esmaillzadeh A
Clin Nutr; 2015 Aug; 34(4):586-92. PubMed ID: 25300649
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Jamilian M; Sabzevar NK; Asemi Z
Horm Metab Res; 2019 Feb; 51(2):100-105. PubMed ID: 30286483
[TBL] [Abstract][Full Text] [Related]
20. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?
Kauffman RP; Baker TE; Baker V; Kauffman MM; Castracane VD
Gynecol Endocrinol; 2010 Jan; 26(1):39-46. PubMed ID: 20001571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
